Imagine this interesting and perhaps very real-life scenario. It could have several implications for the present biosimilar marketing picture. A reference manufacturer, we’ll call them Arby, signs multiple licensing deals with biosimilar manufacturers, to launch their products sequentially in 2025. The licensing deals all conclude outstanding patent litigation between the parties. But one biosimilar manufacturer … Continue reading The Potential Effect of Amgen’s Launch on Biosimilar Licensing Deals →